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Porcine model of progressive cardiac 
hypertrophy and fibrosis with secondary 
postcapillary pulmonary hypertension
Mariann Gyöngyösi1*, Noemi Pavo1, Dominika Lukovic1, Katrin Zlabinger1, Andreas Spannbauer1, 
Denise Traxler1, Georg Goliasch1, Ljubica Mandic1, Jutta Bergler‑Klein1, Alfred Gugerell1, Andras Jakab1, 
Zsuzsanna Szankai1, Levente Toth2, Rita Garamvölgyi2, Gerald Maurer1, Frederic Jaisser3, Faiez Zannad4, 
Thomas Thum5, Sándor Bátkai5 and Johannes Winkler1
Abstract 
Background: Meaningful translational large animal models for cardiac diseases are indispensable for studying dis‑
ease mechanisms, development of novel therapeutic strategies, and evaluation of potential drugs.
Methods: For induction of heart failure, cardiac hypertrophy and fibrosis, a bare metal stent was implanted in the 
descending aorta of growing pigs (n = 7), inducing pressure stress on the left ventricle (group HYPI). The constant 
stent size in growing pigs resulted in antegrade partial obstruction of the aortic flow with a gradual increase in after‑
load. Five pigs with sham intervention served as control. Serial haemodynamic, pressure–volume loop measurements 
and transthoracic echocardiography (TTE) were performed to detect developing pressure overload of the LV and 
cardiac MRI with late enhancement for measuring LV and RV mass and ejection fraction.
Results: At 5‑month follow‑up, CT and contrast aortography, and intraluminal echocardiography confirmed aor‑
tic isthmus stenosis with a mean trans‑stenotic gradient of 64 ± 13.9 mmHg. Invasive haemodynamic measure‑
ments revealed a secondary increase in pulmonary artery pressure (44.6 ± 5.1 vs 25.9 ± 6.2 mmHg, HYPI vs control, 
p < 0.05). TTE and ex vivo analyses confirmed severe concentric LV hypertrophy (mean circumferential wall thickness, 
19.4 ± 3.1, n = 7 vs 11.4 ± 1.0 mm, n = 5, HYPI vs controls, p < 0.05). The LV and RV mass increased significantly, 
paralleled by increased isovolumic relaxation constant (tau). Histological analyses confirmed substantial fibrosis and 
myocyte hypertrophy in both LV and RV. Expressions of ANP, BNP, and miRNA‑29a were up‑regulated, while SERCA2a 
and miRNA‑1 were down‑regulated. Plasma NGAL levels increased gradually, while the elevation of NT‑proBNP was 
detected only at the 5‑month FUP.
Conclusion: These data prove that percutaneous artificial aortic stenosis in pigs is useful for inducing clinically rel‑
evant progredient heart failure based on myocardial hypertrophy and fibrosis.
Keywords: Cardiac hypertrophy, PET‑MRI imaging, Aortic isthmus stenosis, Translational large animal model, Gene 
expression
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Background
Cardiac hypertrophy is an adaptive response to several 
cardiovascular disorders including volume- or pressure 
overload, cardiomyopathies, gene mutations, or loss of 
contractile mass after myocardial infarction [1]. Hyper-
trophic growth accompanies many heart diseases such 
as hypertension, ischemia, and valvular diseases. An 
increasing disease burden is attributed to patients with a 
phenotype cluster of adiposity, hyperlipidemia, and dia-
betes [2]. Persisting hypertrophy progresses to heart fail-
ure with its broad palette of clinical consequences such 
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as intensive medical treatment, increased hospitalization 
and mortality or malignant arrhythmia.
Myocardial fibrosis is characterized by activation of 
fibroblasts to a myofibroblast phenotype, and diffuse 
interstitial collagen deposition. On the molecular level, 
myocardial fibrosis is the result of the imbalance of pro-
fibrotic factors such as growth factors and hormones, 
which result in enhanced synthesis of cross-linked colla-
gen types I and III, and a reduced collagen degradation 
by matrix metalloproteinases and anti-fibrotic factors, 
such as adipokines, or natriuretic peptides [3].
Blocking neurohumoral activation and relieving hemo-
dynamic overload is the current standardized treatment 
of heart failure in the clinical practice. However, because 
of the molecular complexities of cardiac hypertrophy, 
fibrosis, and heart failure, new strategies are focusing 
on intervention on the intrinsic cardiac responses at the 
cardiomyocyte, interstitial and the intravascular level. In 
order to test new potential treatment regimens, adequate 
and meaningful animal models are necessary.
To mimic secondary cardiac hypertrophy, surgical 
interventions in rodents are frequently used [4]. A partial 
occlusion of the ascending or descending aorta by a liga-
ture or clip (aortic banding) in rodents which is followed 
by an abrupt increase in pre-occlusion pressure is most 
commonly used to model left ventricular hypertrophy 
(LVH) caused by aortic stenosis [5, 6]. Other available 
technologies include genetic manipulation, gradual aor-
tic constriction through banding, and pulmonary or renal 
artery constriction, recently reviewed in [7]. However, 
while mouse and rat models have allowed for impor-
tant observations, their translational value is restricted 
because of anatomical and molecular divergence from 
humans. In contrast, several large animals and particu-
larly pigs better resemble human anatomy and (patho)
physiology and are therefore important for translational 
cardiovascular research.
Surgical aortic banding was shown to trigger cardiac 
hypertrophy in pigs [8], inducing abrupt pressure over-
load of the left ventricle (LV), which might be accom-
panied by acute increase in wall stress leading to acute 
heart failure [9]. Yarbrough et al. reported the induction 
of pressure overload in pigs by progressive cuff infla-
tion of the ascending aorta over a period of 4 weeks [10]. 
While LV ejection fraction was preserved, LV mass was 
increased rapidly twofold. A less invasive approach to 
induce chronic LVH and heart failure with preserved 
ejection fraction (HFPEF) was reported by implantation 
of a 90-day-release subcutaneous depot of the aldos-
terone agonist deoxycorticosterone acetate (DOCA) in 
pigs together with a Western diet of salt, sugar, and fat 
[11]. Increased levels of blood cholesterol and triglycer-
ides were found, and a moderate hypertrophy developed 
during the 3-month follow-up [11]. This method seems 
to be the most appropriate one for mimicking human 
metabolic syndrome and gradual development of hyper-
tension and its haemodynamic consequences (e.g. 
diastolic dysfunction) to date. However, chronic admin-
istration of DOCA directly elevates renin-aldosterone 
system biomarkers, and therefore the measurement 
of standard heart failure markers may not be really 
informative.
We aimed to develop a large animal model of percuta-
neous artificial aortic isthmus stenosis induced by per-
cutaneous implantation of peripheral bare metal stents 
(BMS) in descending aorta of juvenile pigs as the constant 
size of stent in growing pigs results in an antegrade par-
tial obstruction of the aortic flow with gradual increase in 
afterload. With this method, we were able to successfully 
create chronic LVH, diastolic dysfunction and second-
ary pulmonary hypertension predicting HFPEF for use in 
translational research.
Methods
Study design
Figure  1 shows the study design. Based on our prelimi-
nary experiences with this model, a 5-month follow-up 
period was optimal for a gradual and steady development 
of left ventricular hypertrophy with simultaneous slow 
increase of the pulmonary arterial pressure. The study 
was terminated after 5 months due to increasing risk of 
LV hypertrophy complications, such as decompensation 
of the aortic stenosis inducing pulmonary congestion or 
lethal arrhythmias.
Animal preparation
Domestic pigs (male, 15 kg, n = 12) were fasted overnight 
and were sedated with 12 mg/kg ketamine hydrochloride, 
0.04 mg/kg atropine and 1.0 mg/kg xylazine, followed by 
intratracheal intubation. The anesthesia was then con-
tinued with 1.5–2.5 vol% isofluran, 1.6–1.8 vol%  O2 and 
0.5 vol%  N2O. During anesthesia, continuous monitor-
ing of the  O2 saturation and ECG were performed. After 
surgical preparation of the right femoral artery and vein, 
200  IU/kg unfractionated heparin was administered 
intravenously, and 6F introducers (Medtronic, Minne-
apolis, MN, USA) were placed in both vessels. In order 
to prevent acute or subacute stent thrombosis, dual 
oral antiplatelet medication (75 mg clopidogrel, 100 mg 
aspirin) was given for 1-month after stent implantation, 
followed by continuous treatment with 100  mg per os 
aspirin until the end of the experiment.
Transthoracic echocardiography (TTE) (GE, Chicago, 
IL, USA) was performed at baseline, and at the 2, 3, 4 
and 5 month FUP to measure left ventricular (LV) dias-
tolic wall thickness of the septum and posterior wall in 
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M-mode and 4-chamber view, and to measure the dias-
tolic function of the left ventricle by pulsatile wave Dop-
pler, including A- and E-wave velocity and e′.
Right heart catheterization was performed via 5F pig-
tail (Cordis, a CardinalHealth Company, Dublin, OH, 
USA) catheter, and the pressures of the right atrium 
(RA) and ventricle (RV) and pulmonary artery (PA) were 
measured. The left heart cathetherization was performed 
with another 5F pigtail catheter (Cordis, a Cardinal-
Health Company, Dublin, OH, USA) measuring the pres-
sures of the left ventricle (LV), ascending and descending 
aortae immediately after the arcus aortae (proximal to 
implanted stent) and at the diaphragma level (distal to 
implanted stent). Pressure–volume (PV) loop investiga-
tion was performed using the Powerlab Equipments and 
software, adapted for large animals (ADInstruments, 
Dunedin, New Zealand).
After completing the baseline investigations, bare 
metal stents (9 mm of diameter, 20 mm of length, Cordis 
S.M.A.R.T. CONTROL, Cordis, Fremont, California) 
were implanted in the descending aorta immediately 
under the arcus aortae (Figs. 1 and 2) in 7 pigs (HYper-
trophic PIgs, Group HYPI), while sham procedures were 
performed in 5 pigs (Group Control). Pressures of the 
ascending and descending aortae pre- and post-stent 
were measured via the pigtail catheter.
After the final MRI investigation at the 5-month fol-
low-up, during continuous deep anaesthesia (1.5–2.5 
vol% isofluran, 1.6–1.8 vol%  O2 and 0.5 vol%  N2O), the 
pigs were administered an additional dose of intravenous 
heparin (10,000 U). Euthanasia was performed by giving 
10  mL intravenous saturated potassium chloride (10%), 
in accordance with accepted guidelines.
Follow‑up investigations
Serial TTE and invasive ascending and descending aorta 
pre- and post-stent, LV, RV, RA and PA pressures were 
measured at 2, 3, 4 and 5-month FUP. PV loop measure-
ments were performed at 3 and 5  month time points. 
Diameters of the descending aorta were measured at 
the site of the stent, pre-stent (proximal to stent) and 
post-stent (distal to stent) in HYPI animals, and at the 
Fig. 1 Schematic illustration of the development of artificial aortic isthmus stenosis. HYPI: group of cardiac hypertrophy. The implanted stent 
became ingrown in the aorta wall, and its constant size does not allow the normal growth (lateral and longitudinal) of the descending aorta at the 
site of the stenting. Note the pre‑ and post‑stenotic dilation of the descending aorta adjacent to the stent, due to the turbulent flow
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corresponding places in controls. Mild oversizing of the 
stent was chosen to avoid slipping of the stent to a distal 
location.
Additionally, aortography by computer tomography, 
intraluminal echocardiography (ILE) and magnetic reso-
nance imaging with late enhancement (MRI + LE) were 
performed to measure stenosis grade, LV and RV systolic 
function and myocardial fibrosis at the end of the experi-
ments. The final CT and MRI + LE was performed within 
1  day of angiography and final invasive measurements, 
followed by immediate scarification of the animals.
Descriptions of the imaging modalities are detailed in 
the Additional file 1.
The animals were sacrificed 5  months after stent 
implantation, and the hearts were explanted. Myocar-
dial tissue and plasma samples were collected for further 
analyses. Myocardial tissue samples from the LV, RV, RA 
and left atrium (LA) were immediately transferred to 
either RNAlater solution (Qiagen, Germany) or 7.5% for-
malin. For histological sections, tissues were embedded 
in paraffin and cut to 4–5 µm slices. For quantification of 
collagen and fibrosis, the samples were stained with HE, 
PicroSirius Red and MOVAT pentachrome and micros-
copy photographs were taken on an Olympus microscope 
IX83. For histological analyses, samples with similar 
orientation and with interstitial collagen staining were 
selected. Fibrosis, i.e. collagen quantity, was assessed by 
computerized planimetry by using ImageJ using thresh-
olding of stained images. Myocyte cross-sectional areas 
were calculated with Olympus CellSens Dimension soft-
ware by manually defining cell borders, using an average 
of at least forty cells per sample.
The animal studies were approved by the local Ethical 
Committee of the Experimental Animal Care Committee 
of the University of Kaposvar, Hungary.
Gene expression analyses
For RNA isolation, tissue samples of around 25 mg were 
cut to small pieces, transferred to 700 µL Qiazol solution 
and homogenized using a Precellys system (Peqlab, Ger-
many). Total RNA including small RNA was extracted 
using the miRNeasy Mini Kit (Qiagen, Germany) on a 
Qiacube according to the manufacturer’s instruction. 
RNA quantities were assessed on a Nanodrop 1000 
(Thermo Fisher). RNA quality was checked on RNA 
Nano chips on the Agilent 2100 Bioanalyzer (Agilent 
Technologies). All samples resulted in RIN values over 7 
and intact 18S and 28S bands.
For mRNA quantification, RNA was transcribed to 
cDNA using the Qiagen QuantiTect Kit according to 
the manufacturer’s instructions and qPCR was per-
formed using the Qiagen qPCR Sybr Green Kit with 
Fig. 2 Study design. HYPI group of cardiac hypertrophy, TTE transthoracic echocardiography, cath catheterization, CT computed tomography, PV-
loop pressure–volume loop measurements, angio angiography, MRI magnetic resonance imaging
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gene specific primers (ANP forward: CAGGAGGGGGA 
AACCAGAAAG, reverse: CAGCAAATTCTTGAAATC 
CATCAGG, BNP forward: CGCAGTAGCATCTTCCAA 
GTC, reverse: ACCTCCTGAGCACATTGCAG, Serca2a 
forward: TTTCGCTCGAGTTGAACCTT, reverse: GAG 
CAGGAGCATCATTCACA, beta-Actin forward: TCA 
ACACCCAGCCATGTAC, reverse: CTCCGGAGTCCA 
TCACGATG) on an Applied Biosystems 7500 Fast qPCR 
system (Thermo Fisher). The mean of two technical rep-
licates was used for each individual sample. A standard 
curve was prepared and run for each gene for assessing 
PCR efficiency. Expression quantities are expressed rela-
tive to beta-Actin.
Sequences of pig miRNAs were derived from the miR-
Base database [12]. For miRNA quantification small 
RNAs were transcribed to cDNA using the Qiagen miS-
cript II RT Kit according to the manufacturer’s instruc-
tions and qPCR was performed using the Qiagen qPCR 
Sybr Green Kit with the Universal Primer and an miRNA 
specific primer (mir-1: GCAGTCTGGAATGTAAAG 
AAG, mir-29a: CGGACCTAGCACCATCTGAA, let7a: 
GCAGTGAGGTAGTAGGTTGT, miR-26: GCACGG 
TTCAAGTAATCCAGG, miR-27: GCTAGTTCACAGT 
GGCTAAG, Qiagen miScript primer assay for RNU6B). 
The mean of two technical replicates was used for each 
individual sample. Expression rates were corrected for 
PCR efficiencies using dilution curves and the expres-
sions of the candidate reference genes (let7a, miR-26, 
miR-27, RNU6B) were entered in Normfinder [13] for 
identification of the most stable transcripts. Accordingly, 
miRNA expression was analyzed in relation to the geo-
metric mean of miR-27 and let7a.
Statistical analyses
Statistical significance was calculated by testing HYPI 
(n = 7) vs control animals (n = 5) using one-way ANOVA 
with repeated measurements, testing the between-group 
differences. In case for which the difference was sig-
nificant, we supplemented the statistical comparison 
with two-sided t-tests. For statistical comparison of the 
groups, the parameters were assigned to the following 
imaging clusters: TTE, invasive pressure measurements, 
cardiac MRI, PV loop, histology, circulating biomarker 
and qPCR. Interdependent parameters determined from 
the same curve or figure (e.g. maximal and minimal val-
ues of the same measure or one parameter is a derivate of 
another parameter) were accounted as one measurement. 
The levels of statistical significance were determined after 
Bonferroni correction for the following imaging groups: 
invasive pressure measurements (p < 0.005), cardiac MRI 
(p < 0.01), PV loop measurements (p < 0.01) and qPCR 
(p < 0.01). For TTE, histology and circulating biomarker 
comparisons (≤  5 parameters were compared) p  <  0.05 
was considered as statistically significant. All analyses 
were performed by an independent observer, who was 
unaware of the treatment groups.
Results
Imaging of experimental aortic isthmus stenosis
The diameters of the descending aorta are listed in 
Table 1. Figure 3a–c display the stent in the descending 
aorta immediately after implantation by contrast aortog-
raphy and computed tomography in the juvenile pigs. 
At 5-month follow-up, images of the descending aorta 
showed the stent with in-stent and distal persistent ste-
nosis in each case confirmed by computed tomography, 
with severely compromised flow through the stenosis 
confirmed by perfusion MRI angiography (Fig.  3d–f). 
ILE of the descending aorta displayed the stent, and 
the persistent connective tissue hyperplasia with nar-
rowed lumen of the aorta at the stent level, accompanied 
by prestenotic dilation of the aorta and turbulent flow 
within the stent (Fig.  4a–c). Continuous wave Doppler 
revealed a mean transstenotic gradient of 55 ± 6 mmHg 
(Fig. 4d). TTE (Fig. 4e) and cardiac MRI (Fig. 4f ) revealed 
thickened myocardium, with developing diastolic dys-
function at the 5-month follow-up.
Serial TTE data of the LV hypertrophy
Serial TTE revealed developing severe concentric LVH 
with an end-diastolic septum and posterior wall thick-
ness of 19.6 ± 2.2 and 15.8 ± 1.3 mm (mean circumfer-
ential 19.4 ±  3.1  mm, n =  7), respectively, in the HYPI 
group at the final follow-up, in contrast with the normal 
wall thickness in controls (11.4 ±  1.0, n =  5). The final 
E/A ratio was 0.92 ± 0.56, E/e′ ratio 9.2 ± 1.5 (Table 2, 
Fig.  4e), indicating diastolic dysfunction in the HYPI 
group. No correlation was found between the E/e` 
ratio and the LV end-diastolic pressure, similar to data 
reported earlier by Previtali et al. [14].
Serial invasive pressure measurements of experimental 
myocardial hypertrophy
The PV loops showed typical features of LVH with 
increased peak systolic pressure and decrease in stroke 
volume (Fig. 5).
Control contrast angiography of the descending aorta 
showed slip of the stent to a position more distal (to the 
diaphragmal level) in 2 animals (stent diameter of 9 mm 
proved still to be too small), which, however, did not mit-
igate the LVH development.
Serial left and right heart catheterization revealed 
increasing transstenotic gradient with parallel increase 
in LV systolic, and end-diastolic pressure, as well as sig-
nificant increase in pressures in the right heart. The sec-
ondary increase in systolic and diastolic right ventricular 
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pressure, and pulmonary pressure reached significance at 
the 5-month follow-up (Fig. 5, Table 2).
Serial data of the PV-loop measurements are shown in 
Table  3. According to the increase in systolic and end-
diastolic pressures of the LV, the end-systolic (ESPVR) 
and end-diastolic pressure volume relationship (EDPVR) 
curves showed leftward shift of the curves (Fig. 5).
cMRI + LE results
Five-month cMRI  +  LE showed preserved LV ejection 
fraction (EF), with a trend to a decrease in right ventricu-
lar EF. In parallel with the significant increase in LV mass, 
the LV peak filling rate decreased in the HYPI animals, 
confirming the TTE findings. This model might also be 
considered as a model of heart failure with preserved EF 
(HFPEF).
Obduction and histology
After the 5-month follow-up, the obduction revealed 
macroscopic constriction of the aortic part with the stent 
with pre- and post-stenotic dilation of the aorta (Fig. 6a, 
b). The slowly developing aortic isthmus stenosis with 
consequent rise in pre-stent systolic blood pressure was 
caused by the increasing mismatch of the stent and the 
increasing aorta diameter in the growing animals. The 
stent intimal hyperplasia was negligible. One stent was 
pulled more proximal during the extension of the aorta 
by the normal growing body and broke at the proximal 
part (Additional file  1: Figure S1) without any clinical 
signs or aortic wall rupture. Macroscopic severe concen-
tric myocardial hypertrophy was found in every animals 
in the HYPI group, compared to the normal wall thick-
ness of controls (Fig. 6c, d). The lungs of the HYPI ani-
mals showed mild macroscopic congestion, evidenced by 
reddish coloration of the lung tissue (not shown).
Histological preparations and staining of the LV myo-
cardial tissue with PicroSirius red and an anti-collagen 
antibody showed a significant increase of collagen depo-
sition as a characteristic feature of tissue fibrosis (Fig. 6e–
g). The degree of the LV and RV fibrosis were significantly 
(p < 0.05) higher with 11.8 ± 2.0 and 8.2 ± 2.5% in the 
HYPI and 1.9 ± 0.4 and 2.2 ± 0.9% in the control group 
Table 1 Diameter of the descending aorta measured by angiography at monthly intervals
The implanted 9 mm diameter stent was slightly oversized in order to prevent the moving of the stent to distal. The constant size of the stent in the growing aorta 
resulted in an artificial stenosis at the mid part of the descending aorta with pre- and post-stenotic dilation
Prox proximal, Dist distal, Stent* diameter of the mid descending aorta at the place of the stent
Time HYPI (n = 7) Co (n = 5) p value
mean SD mean SD
Baseline
 Mid Ao desc 8.46 0.33 8.38 0.26 0.674
 Prox Ao desc 8.64 0.46 8.50 0.16 0.523
 Dist Ao desc 8.51 0.44 8.44 0.17 0.730
1 month
 Mid Ao desc Stent* 9.06 0.08 10.28 0.68 0.001
 Prox Ao desc 12.44 0.68 12.22 0.76 0.606
 Dist Ao desc 11.70 1.27 11.50 0.88 0.768
2 months
 Mid Ao desc Stent* 9.07 0.08 12.32 0.86 0.000
 Prox Ao desc 14.11 0.61 13.60 0.79 0.232
 Dist Ao desc 13.39 0.68 12.72 0.72 0.132
3 months
 Mid Ao desc Stent* 9.11 0.09 15.00 1.12 0.000
 Prox Ao desc 16.26 0.94 15.52 0.91 0.205
 Dist Ao desc 15.01 0.64 14.02 1.06 0.070
4 months
 Mid Ao desc Stent* 9.14 0.13 16.72 1.11 0.000
 Prox Ao desc 19.21 0.65 18.02 1.28 0.058
 Dist Ao desc 16.36 0.98 15.54 0.97 0.183
5 months
 Mid Ao desc Stent* 9.17 0.15 18.29 1.34 0.000
 Prox Ao desc 22.14 1.11 20.61 0.85 0.028
 Dist Ao desc 18.46 0.80 16.77 0.67 0.003
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for LV and RV, respectively. The LV cardiomyocyte cross-
sectional areas were higher in both the HYPI LV and the 
HYPI RV compared to control groups (1002 ± 255 µm2 
vs 527  ±  122  µm2 for LV and 627  ±  91  µm2 vs 
385 ± 100 µm2 for RV; p < 0.05).
Circulating biomarkers of cardiac fibrosis
Plasma NGAL increased significantly after 2  months, 
when the myocardial hypertrophy was clinically not yet 
pronounced, reached a plateau at 3  months (Fig.  7a). 
In contrast the plasma proBNP increased only at the 
5 months follow-up (Fig. 7b).
Molecular markers of cardiac hypertrophy and fibrosis
To confirm the changes associated with cardiac hypertro-
phy on the molecular level, we examined the expression 
of genes known to be up or down regulated in response 
to hypertrophy. As expected, the natriuretic peptide ANP 
and BNP, which are only marginally expressed in adult 
ventricular tissue under normal circumstances, show 
enhanced expression levels in the LV tissue in hyper-
trophic pigs. LV ANP expression was increased more 
than threefold, and BNP levels more than twofold com-
pared to the values of the control animals (Fig.  8a). In 
contrast, the mRNA levels were not significantly altered 
in the LA, RA and RV (Fig. 8a). SERCA2a expression was 
decreased to 71% in the LV and to 48% in the LA (Fig. 8a).
We also examined the expression of selected micro-
RNAs, which have been described to play a role in car-
diac hypertrophy and fibrosis in animal models and in 
the human pathologic condition. We found depletion of 
the cardiomyocyte growth-repressing miR-1 to 50–66% 
in both the LV and RV of pigs with cardiac hypertrophy 
(Fig. 8b). In addition, miR-29a expression was increased 
2- to 3-fold in the RV and LV, respectively.
Discussion
For the development of novel and better treatment 
options for cardiac hypertrophy and fibrosis, relevant 
and reliable translational animal models are necessary. 
Here for the first time we report a percutaneous method 
to create slowly developing pressure overload of the LV 
causing pre-stenotic systolic hypertension, myocardial 
hypertrophy with LV diastolic dysfunction and secondary 
Fig. 3 Creation of artificial aortic isthmus stenosis and myocardial hypertrophy in pigs via percutaneous stent implantation in the descending aorta. 
a Contrast angiography in a farm pig (15 kg) immediately after implantation of a bare metal stent (0.9 mm diameter, 20 mm length). b Computed 
tomographic (CT) aortography shows the location of the stent in anteroposterior view immediately after implantation. c Contrast‑enhanced CT 
(lateral view) after stent implantation. d Magnetic resonance imaging (MRI) 5 months after stenting of the descending aorta displays the stent (red 
arrow), the pre‑ and poststenotic dilation (yellow arrows). Anteroposterior view. e Contrast enhanced MRI at 5‑month follow‑up shows the severely 
limited flow (yellow arrow) through the stent (red arrow). Lateral view. f Systolic frame from phase‑contrast MRI cines; Aorta thoracalis, diameter: 
15 mm, stent diameter: 9 mm, aliasing signal‑fast moving blood in the stent area. (Maximum velocity 300 m/s equivalent with 56 mmHg pressure 
gradient on trough–plane images); 5‑month follow‑up
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pulmonary hypertension in a relevant translational large 
animal model. The internally placed stent, in-grown in 
the aortic wall, precluded the normal extension of the 
aorta during the normal body growth. Comprehensive 
serial invasive hemodynamic measurements with serial 
TTE and ILE imaging allowed detailed monitoring of the 
gradual development of cardiac hypertrophy and fibro-
sis, confirmed by cardiac MRI and CT. Together with 
macroscopic and histological observations, these data 
show that the model is closely related to the condition of 
human heart failure and myocardial fibrosis by hyperten-
sion and aortic stenosis. Important new insights gained 
from this study are the animal model of progressing heart 
failure, with development of postcapillary pulmonary 
hypertension, and high translational value for the transi-
tion of HFPEF to HFREF.
Recognizing the necessity of large animals for mod-
eling human cardiac diseases, surgical aortic banding of 
the aorta has been performed in pigs, inducing abrupt 
changes in the hemodynamics, causing acute heart fail-
ure [9, 15] or by implanting subcutaneous DOCA-depots 
[11] combined with Western diet. In contrast to these 
methods, our procedure is the first minimal invasive per-
cutaneous intervention method, mimicking the gradual 
development of aortic stenosis paralleled by severe LV 
hypertrophy, diastolic dysfunction and secondary (post-
capillary) pulmonary hypertension. In contrast with pre-
vious reports with shorter monitoring times post-aortic 
banding, the longer follow-up (5-month) and steady 
progression of the hemodynamic changes due to artifi-
cial aortic stenosis corresponds more closely to human 
conditions. The longer follow-up period also allowed us 
to the development of post-capillary pulmonary hyper-
tension, which has not been described previously. The 
elevated pressures in the right heart due to LV diastolic 
dysfunction are equivalent to HFPEF. Up to now, by 
either aortic banding or a DOCA infusion pump, no data 
were reported on pressure changes of the right heart. 
Using serial measurements of the left and right heart 
haemodynamics with pig tail catheter and LV pressure–
volume loop measurements, we confirmed the slowly 
developing increase in pre-stenotic systolic pressure with 
a trans-stenotic gradient up to mean 64 mmHg, accom-
panied by significantly increased stroke work and severe 
concentric LV wall thickening (circumferential wall 
thickness of mean 19  mm) confirmed by TTE, cardiac 
MRI and finally with ex vivo investigations. The gradual 
increase in transstenotic gradient and severe concentric 
Fig. 4 Imaging of aortic isthmus stenosis and development of myocardial hypertrophy. a−d Intraluminal echocardiography proximal to stent (a), 
in stent (b) and distal to stent (c) in the descending aorta 5 months after percutaneous stent implantation showing narrowing of the aorta in the 
stent level with tissue proliferation between the stent and the growing aorta in juvenile pigs (b). d Pulsatile Doppler measurements of the trans‑
stenotic gradient. e M‑mode echocardiography displays concentric hypertrophy 5 month after creation of artificial aortic isthmus stenosis (lower 
panel) as compared to normal (upper panel). f Long axis cardiac magnetic resonance imaging confirms the severe concentric hypertrophy in HYPI 
pigs (right panel) in contrast with normal left ventricular myocardium of a control pig (left panel)
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LV hypertrophy induced diastolic dysfunction, evidenced 
by decreased E/A ratio, increased E/e′ ratio by TTE, end-
diastolic pressure of the LV by LV haemodynamics and 
arterial elastance and tau by pressure–volume loop meas-
urements. Parallel with these changes, the plasma NGAL 
level was gradually increased, while a significant plasma 
proBNP level increase was observed only at the 5 month 
follow-up, indicating that NGAL level might be a more 
sensitive early stage heart failure marker.
The end-diastolic volume increased in both groups, 
due to the regular growth of the juvenile pigs, but a trend 
towards LV enlargement was observed in the HYPI ani-
mals as compared to controls, with a trend to lower LV 
and RV EF predicting the development of heart failure 
with reduced ejection fraction (HFREF), if longer fol-
low-up had been done [16]. The transition of HFPEF to 
HFREF has no clear time or disease condition-related 
cut-off, and this process depends on continuous pres-
sure or volume-overload and accompanying diseases 
in humans. Hence, our model with gradually increasing 
pressure overload in the circulation models this on-going 
detrimental progress on the heart well.
Right heart catheterization revealed a gradual increase 
in the RA, RV and pulmonary artery pressures, indicating 
development of post-capillary pulmonary hypertension, 
even if measurements of capillary wedge pressure were 
not performed. Since the animals had no primary lung 
diseases at the obduction, and that the pulmonary hyper-
tension was developed in parallel with the aortic stenosis 
severity, we can exclude a primary pulmonary hyperten-
sion. In contrast with the DOCA-treated animals in the 
experiments of Schwarzl et  al. [11], who classified their 
model as heart failure stage B (ACC/AHA guidelines), we 
observed mild lung congestion of the HYPI animals and 
an elevated pro-BNP level, which correspond with the 
HF stage of C at the final 5-month FUP [17].
According to the echocardiographic circumferential 
wall thickness measurements and the invasive pressure 
measurements, it seems that persistent increase in blood 
pressure for a longer time is necessary for manifest LV 
wall thickening; however, a definitive timely correlation 
between increase in systolic blood pressure and myo-
cardial hypertrophy requires a histological verification, 
Fig. 5 a Typical pattern of the myocardial hypertrophy in pressure‑loop measurement indicating increased systolic pressure and decrease in stroke 
volume at the 5‑month follow‑up in normal (left) and HYPI (right) pigs. b End‑systolic (ESPVR) (upper panel) and end‑diastolic pressure–volume 
relationship (EDPVR) (bottom) showing clear leftward shift of the curves
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necessitating the harvesting of the animals at different 
time-points.
Histology and the changes in expression of cardiac 
mRNAs and miRNAs confirmed the regulation of impor-
tant biomarkers for hypertrophy and fibrosis. The left 
ventricular expression of natriuretic peptides ANP and 
BNP was increased, confirming the cardiac origin of the 
elevated plasma pro-BNP levels. The ventricular expres-
sion of natriuretic peptides is a well-documented result of 
pressure- and volume stress [18, 19] and one of the hall-
marks of congestive heart failure. The endocrine effects 
of ANP and BNP at least partially attenuate pressure- and 
volume stress. The cardiac sarco/endoplasmic reticulum 
 Ca2+-ATPase SERCA2a is instrumental in maintaining 
calcium homeostasis and decreased expression and func-
tion aggravates heart failure [5, 20, 21]. SERCA2a dys-
regulation is one of the key features of heart failure of 
cardiomyocyte dysfunction in both experimental animal 
models and human patients [22], and downregulation 
was verified in the left atrium and left ventricle. These 
changes confirm that the expected molecular pathways 
for cardiac hypertrophy are stimulated in our pig model.
Similarly, several microRNAs that are known to play a 
role in hypertrophy are up or down regulated. Increased 
expression of miR-29a is consistently found in hyper-
trophic animal models and in human heart failure and 
also with cardiac hypertrophy and fibrosis in hyper-
trophic cardiomyopathy patients [23], highlighting their 
Table 3 Serial measurements of the left and right ventricular systolic and diastolic parameters
Data were collected using invasive pressure measurements with pressure–volume loop catheter in hypertrophic pigs (HYPI) and in controls
Italics Parameters characterizing LV hypertrophy
LV left ventricular, RA right atrial, RV right ventricular
*  p < 0.01 for pressure–volume loop and MRI parameter (ANOVA after Bonferroni correction) between the groups at the same time point
Baseline 3 months FUP 5 months FUP
HYPI (n = 7) Control (n = 5) HYPI (n = 7) Control (n = 5) HYPI (n = 7) Control (n = 5)
Invasive pressure–volume loop measurements
 End‑diastolic volume (mL) 87 ± 3 81 ± 6 127 ± 13 109 ± 25 133 ± 12 125 ± 10
 End‑systolic volume (mL) 38 ± 2 32 ± 7 54 ± 6 44 ± 12 53 ± 11 44 ± 4
 Stroke volume (mL) 49 ± 5 49 ± 4 73 ± 8 65 ± 21 78 ± 9 81 ± 14
 LV ejection fraction (%) 56 ± 4 60 ± 7 58 ± 3 59 ± 9 59 ± 4 65 ± 5
 Stroke work (mmHg*mL) 4497 ± 145 4492 ± 1182 8692 ± 1017* 4813 ± 858 9407 ± 1027* 5335 ± 741
 Cardiac output (L/min) 4.0 ± 0.2 4.4 ± 0.4 5.4 ± 0.8 5.2 ± 0.8 5.8 ± 0.8 5.8 ± 0.8
 LV maximal pressure (mmHg) 105 ± 15 118 ± 14 150 ± 11* 124 ± 15 169 ± 18* 120 ± 5
 LV minimum pressure (mmHg) 5 ± 2 2 ± 5 13 ± 3* 6 ± 2 14 ± 3* 6 ± 2
 LV maximum dP/dt (mmHg/s) 1106 ± 164 1203 ± 155 1693 ± 679 1436 ± 136 1883 ± 384 1594 ± 276
 LV minimum dP/dt (mmHg/s) −1492 ± 246 −1485 ± 433 −1741 ± 126 −1620 ± 228 −1911 ± 480 −1616 ± 231
 Mean arterial pressure (mmHg) 57 ± 9 60 ± 22 82 ± 7* 61 ± 4 91 ± 11* 68 ± 3
 LV maximal dV/dt (mL/s) 428 ± 135 428 ± 58 693 ± 94 592 ± 186 527 ± 89* 425 ± 57
 Arterial elastance (mmHg/mL) 2.4 ± 0.4 2.5 ± 0.2 3.0 ± 0.9 2.5 ± 0.3 3.2 ± 0.7* 2.4 ± 0.2
 Tau (ms) 23.8 ± 6.7 25.7 ± 5.8 32.5 ± 1.9 26.8 ± 3.3 39.1 ± 8.2* 24.9 ± 4.7
MRI at 5 months
 LV end‑diastolic volume (mL) 128 ± 16 109 ± 12
 LV end‑systolic volume (mL) 52 ± 10 38 ± 8
 LV stroke volume (mL) 76 ± 12 72 ± 10
 LV ejection fraction (%) 59 ± 6 66 ± 6
 LV mass (g) 151 ± 27 95 ± 17
 RV end‑diastolic volume (mL) 97 ± 13* 78 ± 5
 RV end‑systolic volume (mL) 53 ± 15 37 ± 4
 RV ejection fraction (%) 47 ± 10 52 ± 6
 RV mass (g) 82 ± 9 57 ± 6
 LV peak filling rate (mL/s) 349 ± 114* 514 ± 81
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use as potential biomarker. The microRNA-1 is well doc-
umented to be decreased in heart failure and fibrosis as 
well as animal models of cardiac hypertrophy, similar to 
our model [24, 25].
Limitation
We did not perform MRI at baseline in order to avoid 
exposing the small, 15  kg animals to more stress; MRI 
would have required either an additional anesthesia, or a 
longer anesthesia for transport of the intubated animals 
from MRI to the angiographic lab.
We have measured the dP/dt both with the pigtail 
catheter and also with the piezo transducer of the pres-
sure–volume loop catheter. We are aware that the pig-
tail catheter may underestimate the dP/dt; however, in 
contrast to the pig-tail catheter, the pressure–volume 
loop measurements are very rarely used in humans, and 
we strived for optimal translational value of our experi-
ments. Additionally, the pressures of the pigtail catheter 
were calibrated before each measurement. The 15 kg pigs 
were 1 month old, in “child age” for pigs, with somewhat 
lower normal systemic blood pressure, therefore the dP/
dt values (derivate of systolic pressure and time) around 
1000 mmHg/s measured by the pig tail catheter may be 
considered as being within the normal range.
As the pig heart lies behind the sternum, the usual 
echocardiographic measurements are difficult. The meas-
urements of the left atrium diameter were possible from 
parasternal short axis view, and the Doppler parameters 
from the apical 4-chamber views, while measurement 
Fig. 6 Macroscopic and microscopic imaging of the aortic isthmus stenosis, myocardial hypertrophy and fibrosis. a Explanted descending aorta 
shows pre‑ and poststenotic dilation of the corresponding aorta segments 5‑month after stent implantation (arrow). b Longitudinal cut of the aorta 
displays the stent in the aorta. c and d Left ventricular myocardium in a control animal and in a hypertrophic pig (HYPI), showing severe concentric 
hypertrophy in the HYPI animal. e Anti‑collagen staining of the hypertrophied myocardium shows collagen accumulation as a proof of myocardial 
fibrosis. (left: anti‑collagen staining, right: DAPI counterstaining, bottom: merged). f Histologic images of the left ventricle (LV) and right ventricle 
(RV) of hypertrophic (HYPI) and control animals. HE, Picrosirius red and MOVAT staining display pronounced interstitial fibrosis in the HYPI animals 
both in the LV and RV. g Quantification of fibrosis of the myocardial samples: significantly higher amount of fibrosis in the HYPI animals. Mean ± SD, 
*p < 0.05 (ANOVA) between the control (n = 5) and HYPI groups (n = 7)
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of the other parameters were not possible for all pigs for 
all time points; therefore, we have not reported these 
parameters.
Translational value of artificial percutaneous aortic 
stenosis for human diseases
Induction of gradual development of LV hypertrophy by 
minimally invasive percutaneous approach in our large 
animals successfully simulates human conditions with 
natural progressive sclerotizing aortic stenosis being 
hemodynamically compensated and asymptomatic for a 
long time. This model is in a good agreement with patho-
physiologic concepts of myocardial hypertrophy with 
consequent cardiac fibrosis, hence LV dilation and post-
capillary pulmonary hypertension on the molecular and 
physiological level, offering several molecular targets for 
potential antifibrotic treatment, or preventive medical 
approaches against complications of aortic stenosis. Our 
model is mainly designed for pressure overload induced 
cardiac hypertrophy and progressing heart failure. How-
ever, we believe it can be used as a general model to study 
the cellular and molecular mechanisms of cardiac fibro-
sis, which shares at least some common features regard-
less of the underlying cause (LV adverse remodeling after 
myocardial infarction, cardiomyopathy or others).
Conclusions
Percutaneous implantation of BMSs in the descending 
aorta of juvenile pigs causing slowly developing artifi-
cial aorta isthmus stenosis successfully simulates cardiac 
Fig. 7 Serial measurements of plasma NGAL and proBNP levels. a Rapid increase in NGAL was detected already 2 months after creation of artificial 
aortic isthmus stenosis, even when the transstenotic gradient was not yet significant. b Late elevation of proBNP in the plasma was observed, indi‑
cating a compensatory mechanism of aortic stenosis and developing heart failure. Results are expressed as mean ± SD, *p < 0.05 (ANOVA) between 
the groups at the same time points (n = 7, HYPI, n = 5, control)
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hypertrophy and fibrosis and is in good agreement with 
pathophysiologic concepts of human disease on the 
molecular and physiological level. It is thus a useful 
model for researching molecular mechanisms of hyper-
trophy and for evaluation of potential treatments.
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